Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Zippelius

Showing results (121-130 of 163) with videos related to

Pageof 17
Sort By:
Cell Reports. Medicine|March 25, 2021
Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attackWeldy V Bonilla, Nicole Kirchhammer, Anna-Friederike Marx, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patientsDaniel E Speiser, Katrin Schwarz, Petra Baumgaertner, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 2020
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapyAbhishek S Kashyap, Martina Schmittnaegel, Nicolò Rigamonti, et al.
Nature Immunology|October 6, 2020
Disturbed mitochondrial dynamics in CD8<sup>+</sup> TILs reinforce T cell exhaustionYi-Ru Yu, Hana Imrichova, Haiping Wang, et al.
Cell Reports|September 26, 2019
GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor ResponsesAbhishek S Kashyap, Laura Fernandez-Rodriguez, Yun Zhao, et al.
Clinical Lung Cancer|April 7, 2015
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09Oliver Gautschi, Nicholas Mach, Sacha I Rothschild, et al.
Lancet (London, England)|August 16, 2015
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trialMiklos Pless, Roger Stupp, Hans-Beat Ris, et al.
Nature Immunology|February 19, 2020
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumorsHaiping Wang, Fabien Franco, Yao-Chen Tsui, et al.
Nature Communications|November 21, 2025
Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancerAnaïs Perrichet, Julie Lecuelle, Emeric Limagne, et al.
Science Translational Medicine|July 20, 2022
NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunityNicole Kirchhammer, Marcel P Trefny, Marina Natoli, et al.
Pageof 17

Showing results (121-130 of 163) with videos related to

Sort By:
Pageof 17
Cell Reports. Medicine|March 25, 2021
Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attackWeldy V Bonilla, Nicole Kirchhammer, Anna-Friederike Marx, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patientsDaniel E Speiser, Katrin Schwarz, Petra Baumgaertner, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 2020
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapyAbhishek S Kashyap, Martina Schmittnaegel, Nicolò Rigamonti, et al.
Nature Immunology|October 6, 2020
Disturbed mitochondrial dynamics in CD8<sup>+</sup> TILs reinforce T cell exhaustionYi-Ru Yu, Hana Imrichova, Haiping Wang, et al.
Cell Reports|September 26, 2019
GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor ResponsesAbhishek S Kashyap, Laura Fernandez-Rodriguez, Yun Zhao, et al.
Clinical Lung Cancer|April 7, 2015
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09Oliver Gautschi, Nicholas Mach, Sacha I Rothschild, et al.
Lancet (London, England)|August 16, 2015
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trialMiklos Pless, Roger Stupp, Hans-Beat Ris, et al.
Nature Immunology|February 19, 2020
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumorsHaiping Wang, Fabien Franco, Yao-Chen Tsui, et al.
Nature Communications|November 21, 2025
Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancerAnaïs Perrichet, Julie Lecuelle, Emeric Limagne, et al.
Science Translational Medicine|July 20, 2022
NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunityNicole Kirchhammer, Marcel P Trefny, Marina Natoli, et al.
Pageof 17